Serdar Arısan

Serdar Arısan


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 April 2025 in Medicina
Verified
Journal Article
Open access
PDF file
TKTuğcan Korak
Tuğcan Korak
İBİbrahim Halil Baloğlu
İbrahim Halil Baloğlu
MKMurat Kasap
Murat Kasap
EAElif Damla Arisan
Elif Damla Arisan
GAGürler Akpınar
Gürler Akpınar
SASerdar Arısan
Serdar Arısan
Background and Objectives: Bladder cancer (BLCA), intimately associated with the immune system, represents a substantial global health burden due to its high recurrence rates and limited therapeutic effectiveness. Although immunotherapy shows promise, challenges persist due to the lack of reliable therapeutic targets. This study aims to investigate potential immune-related biomarkers that could influence the tumor microenvironment in BLCA, using proteomic and in silico approaches. Materials and Methods: Tissue samples from BLCA patients (n = 27) and controls (n = 27) were collected from Şişli Hamidiye Etfal Training and Research Hospital. Proteomic analysis was performed by liquid chromatography/mass spectrometry (LC-MS)/MS to reveal the identities of differentially regulated proteins. Protein network analysis and hub protein detection were performed using Cytoscape (v.3.10.3), while functional annotation was carried out using EnrichR. The immunological analysis of hub proteins was performed in Sangerbox platform, and prognostic associations were evaluated through the Kaplan–Meier Plotter tool. Results: LC-MS/MS analysis identified 120 differentially regulated immune-related proteins. STRING analysis, using an immune response dataset (GO:0006955), highlighted the complement cascade as a significantly enriched pathway (p < 0.05). Proteins, namely C4A, CFB, C4B, C8B, CFH, CFI, C5, C4BPA, C3, and C2, that are known to play key roles in the complement system were identified. Immunological analysis with these proteins revealed the phenomena of immune infiltration and immune checkpoint gene associations (p < 0.05). Four hub genes—CFB, C4B, CFI, and C2—demonstrated a significant prognostic value for BLCA (p < 0.05). Conclusions: This study highlights the pivotal role of the complement system in the immune regulation of BLCA. CFI, C4A, and C4B emerged as potential target proteins for BLCA treatment, particularly in immunotherapy, for enhancing survival. Future research on these proteins and the complement system specifically focusing on BLCA may facilitate the development of targeted immunotherapies, ultimately improving treatment outcomes.

6 May 2025 in Biology
Verified
Journal Article
Open access
PDF file
SASerdar Arısan
Serdar Arısan
ASAyyuce Sever
Ayyuce Sever
POPınar Obakan-Yerlikaya
Pınar Obakan-Yerlikaya
EAElif Damla Arisan
Elif Damla Arisan
Pinar Uysal-OnganerPinar Uysal-Onganer
Pinar Uysal-Onganer
Prostate cancer (PCa) is not only one of the most diagnosed malignancies in men but also a leading cause of cancer-related mortality globally. PCa exhibits unique metabolic dependencies, particularly on lipids and glutamine, unlike many solid tumors, rather than glycolysis. Methionine metabolism plays a crucial role in these metabolic pathways, contributing to polyamine biosynthesis, DNA methylation, and cellular signaling processes. Here, we demonstrate that methionine deprivation induces selective vulnerability in AMPK-deficient PC3 PCa cells by disrupting SAMTOR–mTOR signaling and triggering oxidative stress, lipid depletion, and autophagic responses. Through functional and proteomic analyses, we show that SAMTOR directly interacts with p-AMPK and modulates cell fate under methionine-limited conditions. Our findings establish a mechanistic link between methionine sensing and metabolic stress signaling in PCa, offering a new avenue for targeted intervention.

30 May 2025 in Endouroloji Bulteni
Verified
Journal Article
Open access
PDF file
AYAbdulmecit Yavuz
Abdulmecit Yavuz
SASerdar Arısan
Serdar Arısan
Objective: This study aimed to investigate the relationship between Fetuin-A glycoprotein, a known systemic and localized calcification inhibitor, and urinary system stone disease. Material and Methods: A total of 63 patients with urinary stone disease and 70 healthy controls were included. Serum Fetuin-A levels were measured using enzyme-linked immunosorbent assay, and various biochemical parameters were analyzed. Statistical comparisons were performed by using Pearson correlation to determine relationships, with significance set at p0.05). The mean age was 42.87 ± 11.0 years in the stone group and 41.6 ± 11.7 years in the control group (p=0.497). In the stone group, 65% were male and 35% female, while in the control group, 66% were male and 34% female, with no significant difference in gender distribution (p=0.831). Body mass index (BMI) was 25.3 ± 2.57 kg/m² in the stone group and 26.9 ± 3.08 kg/m² in the control group, also showing no significant difference (p=0.067). No correlations were found between serum Fetuin-A levels and other parameters such as age, BMI, or biochemical markers. Conclusion: Although some previous studies have suggested a relationship between Fetuin-A levels and urinary stone disease, this study found no significant association. Further research focusing on genetic polymorphisms of Fetuin-A may clarify its role in stone formation.